|
MechanismKRAS G12C inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date05 Nov 2024 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价 TQC2731 注射液在中度至极重度慢性阻塞性肺疾病患者的有效性、安全性和药代动力学的多中心、随机、双盲、安慰剂对照 Ⅱ 期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety and pharmacokinetics of TQC2731 injection in patients with moderate to very severe chronic obstructive pulmonary disease
主要目的:
评价TQC2731 注射液在中度至极重度慢性阻塞性肺疾病(COPD)患者中的有效性;
次要目的:
评价TQC2731 注射液在中度至极重度 COPD 患者中的安全性、多次给药的药代动力学特征及免疫原性。
[Translation] Primary objective:
To evaluate the efficacy of TQC2731 injection in patients with moderate to very severe chronic obstructive pulmonary disease (COPD);
Secondary objective:
To evaluate the safety, pharmacokinetic characteristics of multiple doses and immunogenicity of TQC2731 injection in patients with moderate to very severe COPD.
100 Clinical Results associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
0 Patents (Medical) associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
100 Deals associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
100 Translational Medicine associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.